These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34988721)
1. Flux-Based Formulation Development-A Proof of Concept Study. Kádár S; Tőzsér P; Nagy B; Farkas A; Nagy ZK; Tsinman O; Tsinman K; Csicsák D; Völgyi G; Takács-Novák K; Borbás E; Sinkó B AAPS J; 2022 Jan; 24(1):22. PubMed ID: 34988721 [TBL] [Abstract][Full Text] [Related]
2. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations. Borbás E; Nagy ZK; Nagy B; Balogh A; Farkas B; Tsinman O; Tsinman K; Sinkó B Eur J Pharm Sci; 2018 Mar; 114():310-317. PubMed ID: 29305981 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133 [TBL] [Abstract][Full Text] [Related]
4. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Miller JM; Beig A; Carr RA; Spence JK; Dahan A Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106 [TBL] [Abstract][Full Text] [Related]
5. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization. Ruponen M; Visti M; Ojarinta R; Laitinen R Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Excipient Risk in BCS Class I and III Biowaivers. Metry M; Polli JE AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701 [TBL] [Abstract][Full Text] [Related]
7. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development. Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248 [TBL] [Abstract][Full Text] [Related]
8. Effect of Formulation Additives on Drug Transport through Size-Exclusion Membranes. Borbás E; Tőzsér P; Tsinman K; Tsinman O; Takács-Novák K; Völgyi G; Sinkó B; Nagy ZK Mol Pharm; 2018 Aug; 15(8):3308-3317. PubMed ID: 29957955 [TBL] [Abstract][Full Text] [Related]
9. Toward Developing Discriminating Dissolution Methods for Formulations Containing Nanoparticulates in Solution: The Impact of Particle Drift and Drug Activity in Solution. Arce FA; Setiawan N; Campbell HR; Lu X; Nethercott MJ; Bummer P; Su Y; Marsac PJ Mol Pharm; 2020 Nov; 17(11):4125-4140. PubMed ID: 32965123 [TBL] [Abstract][Full Text] [Related]
10. Role of Permeability on the Biopredictive Dissolution of Amorphous Solid Dispersions. Ramachandran G; Sudheesh MS AAPS PharmSciTech; 2021 Sep; 22(7):243. PubMed ID: 34595565 [TBL] [Abstract][Full Text] [Related]
11. Investigation and Mathematical Description of the Real Driving Force of Passive Transport of Drug Molecules from Supersaturated Solutions. Borbás E; Sinkó B; Tsinman O; Tsinman K; Kiserdei É; Démuth B; Balogh A; Bodák B; Domokos A; Dargó G; Balogh GT; Nagy ZK Mol Pharm; 2016 Nov; 13(11):3816-3826. PubMed ID: 27611057 [TBL] [Abstract][Full Text] [Related]
12. Bioequivalence requirements in the European Union: critical discussion. García-Arieta A; Gordon J AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032 [TBL] [Abstract][Full Text] [Related]
13. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay. Fine-Shamir N; Dahan A Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762 [TBL] [Abstract][Full Text] [Related]
14. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection. Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs. Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788 [TBL] [Abstract][Full Text] [Related]
16. [Solid State NMR Investigation for Molecular States of Specialized Formulation to Improve the Water Solubility of Poorly Water-soluble Drugs]. Higashi K Yakugaku Zasshi; 2021; 141(9):1063-1069. PubMed ID: 34471007 [TBL] [Abstract][Full Text] [Related]
17. Effect of excipients on the particle size of precipitated pioglitazone in the gastrointestinal tract: impact on bioequivalence. Sugita M; Kataoka M; Sugihara M; Takeuchi S; Yamashita S AAPS J; 2014 Sep; 16(5):1119-27. PubMed ID: 25070482 [TBL] [Abstract][Full Text] [Related]
18. Bioequivalence prediction with small-scale biphasic dissolution and simultaneous dissolution-permeation apparatus-An aripiprazole case study. Kádár S; Kennedy A; Lee S; Ruiz R; Farkas A; Tőzsér P; Csicsák D; Tóth G; Sinkó B; Borbás E Eur J Pharm Sci; 2024 Jul; 198():106782. PubMed ID: 38697313 [TBL] [Abstract][Full Text] [Related]
19. Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery. Ting JM; Porter WW; Mecca JM; Bates FS; Reineke TM Bioconjug Chem; 2018 Apr; 29(4):939-952. PubMed ID: 29319295 [TBL] [Abstract][Full Text] [Related]
20. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk? Veith H; Wiechert F; Luebbert C; Sadowski G Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]